Medi-Cal Rx Monthly Bulletin

October 1, 2026

Medi-Cal Rx has implemented or scheduled the following updates. Stay up to date with all that is happening at Medi-Cal Rx by visiting the Bulletins & News page and signing up for the Medi-Cal Rx Subscription Service to receive notification of future publications.

1. Updates to the Medi-Cal Rx Contract Drugs List
2. Updates to the Medi-Cal Rx Contract Drugs List – Authorized Drug Manufacturer Labeler Codes
3. Updates to the Medi-Cal Rx Contract Drugs List – Over-the-Counter Drugs and Cough/Cold Preparations
4. Updates to the Medi-Cal Rx Family Planning, Access, Care, and Treatment Pharmacy Formulary
5. Updates to the List of Contracted COVID-19 Antigen Tests, Effective January 1, 2027
6. Updates to the Medi-Cal Rx Provider Manual
7. Update: Basaglar® (Insulin Glargine) Removal from the Medi-Cal Rx Contract Drugs List Postponed Until November 1, 2026
8. Medi-Cal Enrollment Requirement to be Implemented in 2027
9. Update: Requirement for Provider Enrollment in Medi-Cal
10. Updates to the Reminder: Provider Enrollment Requirement Not Yet Active
11. Updates to the Claim Submission Reminders
12. Updates to the Medi-Cal Rx CCS Weekly (910) and Monthly (940) Expenditure Report Details Job Aid

1. Updates to the Medi-Cal Rx Contract Drugs List

The following updates have been made to the *Medi-Cal Rx Contract Drugs List* (CDL) and the *Medi-Cal Rx Diagnosis Crosswalk* *.

Drug Name	Description
Albuterol/Budesonide	Added to the CDL with labeler restriction (LR).
Asciminib Hydrochloride	**Effective November 1, 2026:** Prior authorization (PA) required.
Benralizumab *	Additional diagnosis codes added.
Brigatinib	**Effective November 1, 2026:** PA required.
Dapagliflozin Propranediol	LR removed.
Glucagon (synthetic)	Quantity limit (QL) updated for nasal spray.
Iberdomide	Added to the CDL with LR.
Lubiprostone	Added to the CDL.
Naloxegol Oxalate	**Effective December 1, 2026:** PA required.
Patiromer Calcium Sorbitex	Additional strength added to the CDL.
Segesterone Acetate and Ethinyl Estradiol	LR updated.
Zidesamtinib	Added to the CDL with LR.

2. Updates to the Medi-Cal Rx Contract Drugs List – Authorized Drug Manufacturer Labeler Codes

The following updates have been made to the *Medi-Cal Rx Contract Drugs List – Authorized Drug Manufacturer Labeler Codes*.

Labeler Code Additions

NDC Labeler Code	Contracting Company's Name
87519	ANVI PHARMACEUTICALS INC
85347	APHELION LLC
84670	EVITA SOLUTIONS LLC
87450	HIGHMARK PHARMA LLC
85001	NUVALENT, INC.
85866	ORCA BIOSYSTEMS INC.
87668	ORPHAN THERAPIES LLC
66621	RARE DISEASE THERAPEUTICS

NDC Labeler Code	Contracting Company's Name
84897	RENOVA PHARMACEUTICALS LLC
85219	REVOLUTION MEDICINES, INC.
85052	VERA THERAPEUTICS, INC.
87528	VICI PHARMACEUTICALS INC
85166	VIRIDIAN THERAPEUTICS, INC.
85776	WELLHOUSE PHARMA, LLC

Labeler Code Terminations

NDC Labeler Code	Contracting Company's Name
76388	ASPEN GLOBAL INCORPORATED
15584	GILEAD SCIENCES, LLC
00007	GLAXOSMITHKLINE LLC
71269	MAINPOINTE PHARMACEUTICALS LLC
25208	MEDICURE INTERNATIONAL, INC.
55670	MOORE MEDICAL
83035	SINGULAR DREAMER, LTD

3. Updates to the Medi-Cal Rx Contract Drugs List – Over-the-Counter Drugs and Cough/Cold Preparations

The following update has been made to the *Medi-Cal Rx Contract Drugs List – Over-the-Counter Drugs and Cough/Cold Preparations*.

Drug Name	Description
Polyethylene Glycol 3350	Additional package size added to the *Medi-Cal Contract Drugs List – Over-the-Counter Drugs and Cough/Cold Preparations*.

4. Updates to the Medi-Cal Rx Family Planning, Access, Care, and Treatment Pharmacy Formulary

The following change has been made to the *Medi-Cal Rx Family Planning, Access, Care, and Treatment Pharmacy Formulary*.

Drug Name	Description
Segesterone Acetate and Ethinyl Estradiol	LR updated.

5. Updates to the List of Contracted COVID-19 Antigen Tests, Effective January 1, 2027

The *List of Contracted COVID-19 Antigen Tests* has been updated on the Medi-Cal Rx Web Portal. The effective date of the changes is January 1, 2027.

The following product will be deleted from the *List*:

Manufacturer	Product Label Name	Medi-Cal 11-digit Billing Number (NDC)
OraSure Technologies, Inc.	InteliSwab® COVID-19 Rapid Test (2 tests per kit)	08337000158

Note: The Maximum Allowable Product Cost (MAPC) for this product is no longer guaranteed and this test is no longer a Medi-Cal Rx benefit, even with an approved PA. Only tests on the *List* are covered. Members and pharmacy providers should refer to the member's medical benefit for coverage of non-contracted tests. Continuing care does not apply.

6. Updates to the Medi-Cal Rx Provider Manual

The following updates/additions have been made to the *Medi-Cal Rx Provider Manual*.

Section	Update Description
Section 4.6.11 – Non-Standard Benefits/Items Not Covered	• Added information regarding when hormone therapy and puberty blocker drugs used for Gender-Affirming Care (GAC) are excluded from reimbursement.
Section 4.6.19 – Drug Price Override Request (**NEW!**)	• Added a new section regarding drug price override requests.
Section 15.7.2 – Emergency Dispensing for Medi-Cal Enrolled Out-of-State or Out-of-Country Providers	• Updated the section title, added information about billing for emergency services, and added a link to *Section 15.7.4*.
Section 15.7.4 – Non-Emergency Services for Medi-Cal Enrolled Out-of-State or Out-of-Country Providers (**NEW!**)	• Added a new section regarding non-emergency services for Medi-Cal enrolled out-of-state or out-of-country providers.
Appendix G – OHC Carrier Information	• Added carriers to the list of Other Health Coverage (OHC) carriers.

7. Update: Basaglar® (Insulin Glargine) Removal from the Medi-Cal Rx Contract Drugs List Postponed Until November 1, 2026

What Prescribers Need to Know

Medi-Cal Rx has postponed the removal of Basaglar® (insulin glargine), NDC labeler code 00002, from the CDL until November 1, 2026. This postponement ensures members will continue to have access despite the unanticipated supply chain concerns. Claims submitted for this drug without an approved PA, with a date of service (DOS) on or after November 1, 2026, will deny with **Reject Code 606 – Brand Drug/Specific Labeler Code Required**. A PA request demonstrating medical justification for use over a CDL-listed product will need to be submitted for coverage consideration.

What Prescribers Need to Do

- Prescribers should consider alternate covered therapies that are listed on the CDL (such as Lantus® [insulin glargine] or insulin glargine-yfgn), if clinically appropriate. Refer to the *Medi-Cal Rx Approved NDC List* on the Medi-Cal Rx Web Portal.
- If a change in therapy is not appropriate, beginning November 1, 2026, submit a PA request via one of the five approved PA request submission methods demonstrating medical justification:
  - CoverMyMeds®
  - Medi-Cal Rx Secured Provider Portal
  - NCPDP P4 Transaction
  - Fax
  - U.S. Mail

8. Medi-Cal Enrollment Requirement to be Implemented in 2027

Beginning in 2027, in order for pharmacy claims to be processed and paid, the **individual prescriber** on the claim (such as doctors, nurse practitioners, or physician assistants) must be enrolled in Medi-Cal using their individual (Type 1) National Provider Identifier (NPI). This requirement also applies to pharmacists initiating prescriptions under their own scope of practice authority. Affiliation with a managed care plan (MCP) and/or enrollment as a provider with the federal Medicare program is not sufficient to meet the requirements for Medi-Cal enrollment.

» **Prescribers not yet enrolled should immediately submit their Medi-Cal provider enrollment application via the Provider Application and Validation for Enrollment page on the Department of Health Care Services' (DHCS) website.**

Navigate to the Education & Outreach page and select the **Provider Enrollment Requirement** tab for more information. For enrollment questions, navigate to the Provider Inquiry form to submit requests for assistance to DHCS' Provider Enrollment Division (PED).

Refer to DHCS' new Medi-Cal ORP Enforcement Outreach and Engagement page for additional resources, including the recently published Prescribers and Billing Providers FAQ page.

9. Update: Requirement for Provider Enrollment in Medi-Cal

Medi-Cal Rx published the *Update: Requirement for Provider Enrollment in Medi-Cal* alert on September 9, 2026. To access the document, visit the Bulletins & News page on the Medi-Cal Rx Provider Portal or select the **Provider Enrollment Requirement** tab on the Education & Outreach page.

10. Updates to the Reminder: Provider Enrollment Requirement Not Yet Active

Medi-Cal Rx published updates to the *Reminder: Provider Enrollment Requirement Not Yet Active* alert on September 9, 2026. To access the document, visit the Bulletins & News page on the Medi-Cal Rx Provider Portal or select the **Provider Enrollment Requirement** tab on the Education & Outreach page.

11. Updates to the Claim Submission Reminders

Medi-Cal Rx published updates to the *Claim Submission Reminders* on September 30, 2026. To access the document, visit the Medi-Cal Rx Provider Portal and select the **Reference Materials** tab on the Forms & Information page.

12. Updates to the Medi-Cal Rx CCS Weekly (910) and Monthly (940) Expenditure Report Details Job Aid

Medi-Cal Rx published updates to the *Medi-Cal Rx CCS Weekly (910) and Monthly (940) Expenditure Report Details Job Aid* on September 17, 2026. To access the document, visit the Medi-Cal Rx Provider Portal and select the **Medi-Cal Rx Training** tab on the Education & Outreach page.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.